ReviewJournal of natural products2017
Englerins: A Comprehensive Review.
Review in Journal of natural products, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- (-)-Englerin A binding to human TRPC5 exposes an aromatic interaction network in channel activation.Nature communications · 2026Article
- Unprecedented sesterterpenoids, orientanoids A-C: discovery, bioinspired total synthesis and antitumor immunity.Chemical science · 2023Article
- An Investigation of Structure-Activity Relationships and Cell Death Mechanisms of the Marine Alkaloids Discorhabdins in Merkel Cell Carcinoma Cells.Marine drugs · 2023Article
- Ion channels and channelopathies in glomeruli.Physiological reviews · 2023Review
- Biological Effects of Modifications of the Englerin A Glycolate.ACS medicinal chemistry letters · 2022Article
- Review
- An ex vivo perfused ventilated murine lung model suggests lack of acute pulmonary toxicity of the potential novel anticancer agent (-)-englerin A.Archives of toxicology · 2022Article
- Natural products targeting cancer cell dependency.The Journal of antibiotics · 2021Review
- Identification of natural product modulators of Merkel cell carcinoma cell growth and survival.Scientific reports · 2021Article
- (-)-Englerin-A Has Analgesic and Anti-Inflammatory Effects Independent of TRPC4 and 5.International journal of molecular sciences · 2021Article
- Canonical transient receptor potential channels and their modulators: biology, pharmacology and therapeutic potentials.Archives of pharmacal research · 2021Review
- Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.ACS medicinal chemistry letters · 2020Article
- Natural Products as a Foundation for Drug Discovery.Current protocols in pharmacology · 2019Review
- Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype.Breast cancer research and treatment · 2019Article
- Treasure troves of pharmacological tools to study transient receptor potential canonical 1/4/5 channels.British journal of pharmacology · 2019Review
- Tonantzitlolone is a nanomolar potency activator of transient receptor potential canonical 1/4/5 channels.British journal of pharmacology · 2018Article
- Review
- Identification of an (-)-englerin A analogue, which antagonizes (-)-englerin A at TRPC1/4/5 channels.British journal of pharmacology · 2018Article
- The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review.International journal of molecular sciences · 2017Review
- NaScientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In the decade since the discovery of englerin A (1) and its potent activity in cancer models, this natural product and its analogues have been the subject of numerous chemical, biological, and preclinical studies by many research groups. This review summarizes published findings and proposes further research directions required for entry of an englerin analogue into clinical trials for kidney cancer and other conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.